Survodutide: What the Research Says About the Dual GLP-1/Glucagon Agonist
Survodutide is one of the newer names drawing attention in metabolic peptide research — a dual agonist that pairs GLP-1 activity with glucagon-receptor activity. Here is a grounded overview of what the published research currently shows.
What is survodutide?
Survodutide is an investigational peptide that activates both the GLP-1 and glucagon receptors. That combination sets it apart from single GLP-1 agonists and from the GIP/GLP-1 pairing seen in other dual agonists.
How its mechanism differs
By engaging glucagon receptors alongside GLP-1, survodutide is studied for effects on both appetite signaling and energy expenditure. For the wider context of how single, dual, and triple agonists differ, see our GLP-1 agonist guide.
What the trial data shows
In published Phase 2 obesity research, survodutide produced substantial mean weight reductions over the study period, placing it among the more closely watched dual agonists in the literature. As with all such compounds, figures vary by dose and trial duration.
How it compares to carried compounds
Researchers comparing mechanisms often look at survodutide alongside the triple agonist retatrutide, the dual GIP/GLP-1 agonist tirzepatide, and the single GLP-1 agonist semaglutide. Our three-way comparison covers those carried options in detail.
Handling and storage
Dual agonists are supplied as lyophilized powder and reconstituted with bacteriostatic water before use. See our reconstitution guide for general handling.
Research use only. This article is educational and is not medical advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.